PARKVILLE, Mo.--(BUSINESS WIRE)--Bond Biosciences, Inc. “We are pleased to begin this first-in-human clinical trial of our lead non-absorbed oral therapy and thankful for the seasoned development team ...
Robin Meyer was adamant: “We have to do something for this patient.” Meyer, R.N.C. infusion nurse at AHN Cancer Institute at Saint Vincent, identified an urgent and important need for her patient, ...
Rusfertide demonstrated favorable safety, tolerability, and therapeutic effect, decreasing and normalizing average TSAT and iron levels and reducing phlebotomy frequency during the 24-week study Data ...
Rusfertide may eliminate therapeutic phlebotomies in polycythemia vera, showing symptomatic improvement and potential treatment utility. Besremi outperformed anagrelide in essential thrombocythemia, ...
NEWARK, Calif., Dec. 12, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today presented updated data from two ongoing Phase 2 studies evaluating ...
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback